Nuo Therapeutics Q2 Revenue Jumps 150% to $1.77M, Loss Narrows to $167K
AURX is trading near its 52-week low of $0.77 (0.0% above the low).
Summary
Nuo Therapeutics reported Q2 revenue of $1.77M, up over 150% year-over-year, with first-half revenue of $3.07M also up over 150%. The net operating loss narrowed to $167K, a $280K improvement from Q1. The company also amended its loan agreement, securing $675K in interim funding with $325K remaining available. Management confirmed achievement of a reimbursement fee milestone under the Smith+Nephew distribution agreement, with payment expected this quarter. This follows the 10-Q filed August 14 that disclosed a supply chain disruption and going concern doubt; today's release adds specific financial figures and the milestone confirmation. The stock trades near its 52-week low at $0.77, so the revenue growth and narrowing losses are material for a micro-cap with a $37M market cap.
At the time of this announcement, AURX was trading at $0.77 on OTC in the Life Sciences sector, with a market capitalization of approximately $37.3M. The 52-week trading range was $0.77 to $3.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.